Skip to main content
All Posts By

admin

university-of-maryland-um-ventures

Bioentrepreneurship Leader Joins UM Ventures Team

By News Archive

university-of-maryland-um-ventures

University of Maryland Ventures (UM Ventures) announced today that Dr. Martha J. Connolly has been named director of bioentrepreneurship, a new program supported by the Maryland Technology Enterprise Institute (Mtech) and the A. James Clark School of Engineering, designed to enhance collaboration between the University of Maryland, College Park (UMD) and the University of Maryland, Baltimore (UMB) as part of the MPowering the State initiative.

“UM Ventures creates an integrated innovation ecosystem that includes entrepreneurial support resources,” said James Hughes, Chief Economic Development Officer and Vice President at UMB. “Experts like Martha help turn novel ideas into sustainable businesses, and I’m pleased to have her as part of our enterprise.” 

Read More
glaxosmithkline

Glaxo: the New Modern Face of Big Pharma? – The Epoch Times

By News Archive

glaxosmithkline

With billions to be made on the back of ill health and notable scandals and cover-ups in its history, it’s fair to say that many see the public face of the pharmaceutical industry as a mask for darker machinations. We rely on the drugs for myriad conditions, but do we trust big pharma?

Pharmaceutical giant GlaxoSmithKline (GSK) is no stranger to accusations of unethical drug marketing tactics. But recent news coverage has included its support for the AllTrials campaign – which calls for clinical trials to be registered and results to be published – and a package of other initiatives, including a new commitment to end direct payments to doctors (and other key opinion leaders – KOLs) that have been one of the industry’s most powerful marketing tools.

Read More
johns-hopkins-new-logo

Johns Hopkins University Among Six Centers Sharing $540 Million for Cancer Study – Bloomberg

By News Archive

johns-hopkins-new-logo

Harvard University, Johns Hopkins University and Stanford University are among six institutions sharing a $540 million grant for cancer research from funds established by late real estate magnate Daniel K. Ludwig.

Each center will receive $90 million in new grants from the fund established in 2006, bringing the total bequest to each institution to $150 million, said Ed McDermott, president and chief executive officer of New York-based Ludwig Cancer Research, in a press conference. Other centers getting money are Memorial Sloan-Kettering Cancer Center in New York, University of Chicago and the Massachusetts Institute of Technology.

Read More
seed-vc-deal-2013-cbinsights

2013 Seed Investing Snapshot: Seed Venture Capital Financing Hit Four-Year High

By News Archive

seed-vc-deal-2013-cbinsights

2013 has been another banner year in seed financing for U.S. tech startups.  In aggregate, 2013 saw $893 million invested across 843 seed VC deals. In fact, 2013 saw the highest amount of seed VC deals since 2009. Seed VC deal activity in 2013 jumped 11% from 2012 levels and a whopping 173% from 2010 as the number of active seed venture investors continued to stay strong.  By way of definition, seed venture capital rounds included in this brief are early stage investments (typically less than $1.5 million) that specifically include the participation of a venture capital and/or corporate venture capital investor (angel rounds were excluded from this analysis).

Read More

MIMETAS Appoints BHI Entrepreneur-in-Residence Todd Chappell as General Manager, U.S. Affairs

By Uncategorized

Todd-ChappellROCKVILLE AND BALTIMORE, MARYLAND, January 6, 2014 – BioHealth Innovation, Inc. (BHI) and MIMETAS announced today that Todd Chappell, MBA, an Entrepreneur-in-Residence for BHI, has been named General Manager, U.S. Affairs for MIMETAS. A Netherlands-based company, MIMETAS is establishing its offices within BHI’s headquarters in Rockville. MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.

“We’re very pleased to add Todd to the MIMETAS team,” said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. “Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models.”

Previously, Mr. Chappell was the Vice President of Operations for Shape Pharmaceuticals, a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations involved in the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Prior to that, he was at CombinatoRx Inc. for eight years and served as Director of New Products. Mr. Chappell will be combining his role at MIMETAS with his existing EIR position at BHI.

Read More
mimetas

MIMETAS Appoints Todd Chappell as GM, U.S. Affairs

By Uncategorized

mimetasMIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.

“We’re very pleased to add Todd to the MIMETAS team,” said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. “Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models.”

Read Full Article

faes-logo

Advanced Studies in Technology Transfer – Foundation for Advanced Education in the Sciences

By Uncategorized

faes-logo

On Tuesday, January 7th from 4-7 pm there will be an open house for the spring courses in the “Advanced Studies in Technology Transfer” certificate program at the FAES Graduate School at NIH in the new FAES Classroom & Bookstore complex in Building 10 / B1 level. For the semester beginning on January 27th there will be 10 courses available with enrollment open to the general community:

  • TECH 503 – Business Law Primer
  • TECH 506 – Research Commercialization Webinar Course: The Essentials
  • TECH 513 – Introduction to Technology Transfer
  • TECH 562 – How to Get a Job in Technology Transfer ***NEW***
  • TECH 566 – Biotechnology Business Leadership & Management Strategies
  • TECH 582 – Intellectual Property and Patent Prosecution for Scientists
  • TECH 584 – Translational Medical Product Development
  • TECH 586 – International Science, Technology and Innovation Policy
  • TECH 607 – Capstone Course in Technology Transfer
  • PHAR 500 – Principles of Clinical Pharmacology

More details can be found in the spring 2014 course catalog supplement (www.faes.org). Course credit is transferable as well into various MBA & MS degree programs at the University of Maryland University College (UMUC) Graduate School as well as the new Master of Biotechnology Enterprise and Entrepreneurship degree program at Johns Hopkins University.

Read More
bernard-munos-interview-video

Are Pharma Companies Too Big to Innovate? (JNJ)

By News Archive

bernard-munos-interview-video

Ask any investor what they think about Johnson & Johnson (NYSE: JNJ  ) , and you’ll probably hear that it’s a diversified pharma company, a blue-chip stock that pays a hefty dividend, and it’s a relatively safe investment for investors looking for exposure to the health-care sector. But you might also hear investors criticize its size. With a market cap of almost $260 billion, Johnson & Johnson is one of the largest companies in the U.S., and it edges out both Merck and Pfizer as the largest pharma company in the Dow. Can a company this massive be nimble and entrepreneurial enough to innovate? Is its size holding back its long-term potential to bring new products to market?

Read More
jhu-mont-campus-imag

Montgomery County Campus 2013 Year in Review – Johns Hopkins University Montgomery County Campus Blog

By News Archive

jhu-mont-campus-imag

The National Cancer Institute opened NCI Shady Grove next door to the Johns Hopkins Montgomery County Campus buildings. Employees started arriving in late December 2012, two years after the September 2010 groundbreaking ceremony. The move was completed in Spring 2013. Approximately 2,400 NCI employees work at NCI Shady Grove. Coinciding with the arrival of the NCI employees, six new retail shops opened along the parking garage: Shady Grove Cleaners, Freshii, Subway, West Wing Café & Bakery, Blue Fin and Natural Market.

Meanwhile, 11 new companies decided to locate their businesses on campus. These entrepreneurs and researchers focus on health care research and information technology.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.